Activation of Akt signaling pathway has been suggested involving in chemoresistance, metastasis and tumorigenesis of gastric cancer. However, the mechanism of Akt regulation in gastric cancer is not fully understood. RUNX3, which was first identified as a transcription factor, suppresses gastric tumorigenesis through regulating expression of target genes. Here, we found that restoration of RUNX3 significantly downregulates the protein and mRNA expression of Akt1 in gastric cancer cell lines, AGS and SNU-1. Knockdown of RUNX3 upregulates protein and mRNA expression of Akt1 in normal gastric epithelial cell line, GES-1. The negative correlation of RUNX3 and Akt expression and downstream b-catenin/cyclin D1 effectors was further confirmed in AGS and GES-1 cell lines, as well as clinical specimens of gastric cancer. We identified two RUNX3-binding sites in Akt1 promoter and the binding of RUNX3 on Akt1 promoter significantly inhibits Akt1 expression. The RUNX3-mediated inhibition of Akt1 caused b-catenin protein degradation and then cyclin D1 downregulation. Restoration of cyclin D1 reverses cell growth inhibition and G1 phase arrest induced by RUNX3 in gastric cancer cells. Our results show that loss of RUNX3 expression can enhance the Akt1-mediated signaling pathway and promote the tumorigenesis process in human gastric cancer.
Introduction
Gastric cancer is one of the common cancers that often cause high mortality throughout the world Parkin et al., 2005; Hartgrink et al., 2009) . The tumorigenesis process of gastric cancer has been widely studied. Besides environmental factors (Chyou et al., 1990; Nomura et al., 1990; Parsonnet et al., 1991; Tsugane and Sasazuki, 2007; Suzuki et al., 2009; Polk and Peek, 2010) , genetic alterations of oncogenes, tumor-suppressor genes, cell cycle regulators, cell adhesion molecules and DNA repair genes have been identified to contribute to development or progression of gastric cancer (Wu et al., 1997; Zheng et al., 2004; Stock and Otto, 2005) . The gene instability in gastric cancer including gene amplification, loss of heterozygosity (Sano et al., 1991) or microsatellite instability (Fang et al., 2003) may cause the inactivation of some tumor-suppressor genes, such as p53, and deregulation of some signaling molecules so as to enhance some signaling pathways, such as Wnt or Ras-dependent mitogen-activated protein kinase (MAPK) pathway, which may promote the tumorigenesis (Kim et al., 1991; Clements et al., 2002; Stock and Otto, 2005) . In another way, the gene silencing in gastric cancer frequently results from promoter hypermethylation caused by overexpression of DNA methyltransferase 1 and involves many genes expression such as hMLH1, E-cadherin, transforming growth factor (TGF)-b receptor type I and RUNX3 that loss of them may exacerbate the gastric cancer progression (Etoh et al., 2004; Stock and Otto, 2005; Sato and Meltzer, 2006) . The more comprehensive investigations of molecular mechanisms related to gastric carcinogenesis will provide more evidences for developing novel diagnostic and therapeutic strategies against gastric cancer.
The human RUNX gene (the runt-related transcription factor) is the homologue from the Drosophila genes runt (Kania et al., 1990) and lozenge (Daga et al., 1996) and contains highly conserved sequence of 'runt domain', which directs the binding of RUNX protein to DNA via protein-protein interaction with the partner protein CBFb and mediates the transcription activation or repression of the targeted genes (Ito, 1999) . The human RUNX family includes three members: RUNX1/ AML1, RUNX2/CBFA1 and RUNX3/PEBP2aC/ AML2. Three RUNX proteins share similar structures but have distinct functions that involve in different process of mammalian development and organogenesis (Levanon et al., 1994; Otto et al., 2003; Ito, 2004) . Human RUNX3 gene was originally cloned as AML2 by Levanon et al. in 1994 . It locates at chromosome 1 (1p36.1) and has an important role in proliferation, differentiation and maturation of human cells (Fukamachi and Ito, 2004; Fukamachi, 2006; Ito, 2008) . Inactivation or loss of RUNX3 proteins, caused by promoter hypermethylation, loss of heterozygosity on chromosome 1p, point mutation at RUNX3-R122C and protein mislocalization, can be detected in over 80% of gastric cancers (Li et al., 2002; Ito et al., 2005; Yanada et al., 2005; Gargano et al., 2007) . RUNX3 has been regarded as a tumor suppressor that is involved in the TGF-b-mediated signaling pathway by interacting with Smad2/3, Smad4, p300 and FoxO3a to regulate the transcription of target genes (Chuang and Ito, 2010) . RUNX3 suppresses gastric tumorigenesis through upregulating p21 WAF1/Cip1 (Chi et al., 2005) , Bim (Yano et al., 2006) and Claudin-1 (Chang et al., 2010) , and downregulating VEGF (Peng et al., 2006) .
We recently demonstrated that loss of RUNX3 expression was associated with increased lymph node metastasis, reduced cellular differentiation and inferior survival duration in gastric cancer patients. In vitro, reexpression of RUNX3-promoted apoptosis, and inhibited invasion and migration of AGS cells (Hsu et al., 2009) . Although the mechanism of RUNX3-induced apoptosis is clear, the RUNX3-mediated signaling pathway for its tumor-suppressive role is still unknown. One earlier study demonstrated that restoration of RUNX3 in gastric cancer cells could inhibit the cell proliferation and might relate to cyclin D1 downregulation (Wei et al., 2005) . In this study, we show that RUNX3 represses Akt1 expression through transcriptional inhibition, and two RUNX3-binding sites (RBSs) on Akt1 promoter have been identified. The inhibition of Akt1 facilitates b-catenin degradation followed by cyclin D1 downregulation. Our data suggest loss of RUNX3 in gastric cancer prevents G1 phase arrest and promotes tumorigenesis through Akt1/bcatenin/cyclin D1 signaling pathway.
Results
Restoration of RUNX3 causes cell cycle arrest and inhibits cell proliferation We first examined the RUNX3 protein expression in gastric cancer tissues and cell lines including AGS, SNU-1, MCI-N87, KATO III and NUGC-4, as well as human normal gastric epithelial cell line, GES-1, by western blot. Consistent with previous reports, RUNX3 protein was lost or downregulated in gastric cancer tissues and cell lines, but highly expressed in normal tissue and normal gastric epithelial cells, GES-1 (Figure 1a ). Colony-forming assay showed that restoration of RUNX3 in AGS cells significantly reduced the size and number of colonies, compared with mock and vector-only controls (Figure 1b ). In addition, the cell growth was significantly decreased by enforced expression of RUNX3 comparing with parental and green fluorescent protein (GFP)-transfected cells (Figure 1c) . These results indicated the negative role of RUNX3 on proliferation of AGS cells. Similar inhibitory effect of RUNX3 on cell proliferation was also observed in SNU-1 and HeLa cells (data not shown), suggesting that this phenomenon was not cancer-or cell type-specific. Cell cycle analysis showed that the restoration of RUNX3 in AGS cells increased the G1-phase population and decreased the G2/M population when compared with the GFP control (Figure 1d ). This RUNX3-induced G1 arrest was further confirmed by nocodazole treatment showing that 470% cells transfected with GFP plasmid arrested in G2/M phase, whereas most cells transfected with GFP-RUNX3 remained in G1 or S phase ( Figure 1e ). These results indicated that RUNX3 inhibited AGS cells proliferation through blocking the cell cycle progression by arresting cells in G1 phase.
RUNX3 directly represses Akt1 transcription
We next investigated the mechanism of RUNX3-induced proliferation inhibition and cell cycle arrest. From the result of human phospho-MAPK array, decreased levels of phospho-Akt1, phospho-GSK-3a/b and phospho-GSK-3b was observed in RUNX3-overexpressing AGS cells (Figures 2a and b) . The RUNX3-reduced Akt phosphorylation at Thr-308 and Ser-473 was further confirmed by western blot (Figure 2c) . Surprisingly, downregulation of total Akt protein and mRNA were also detected in RUNX3-overexpressing AGS and/or SNU-1 cells (Figures 2c and d, right panel, and Supplementary Figure S3) . By analyzing the endogenous mRNA expression, we identified lower RUNX3 mRNA and greater Akt mRNA levels in AGS and SNU-1 cells than in normal gastric tissues (Figure 2d , left panel). In parallel, knockdown of endogenous RUNX3 by lentivirus-based short hairpin RNA (shRNA) resulted in the upregulation of phosphorylation and protein/mRNA expression of Akt in human normal gastric epithelial cell line GES-1, which expresses higher level of RUNX3 (Guo et al., 2005) ( Figure 1a and Figures 2e and f) . The reverse correlation of RUNX3 and Akt expression was further confirmed by immunohistochemistry in 90 paraffin-embedded gastric cancer specimens (Figure 2g ). In agreement with the negative correlation of RUNX3 and Akt expression, co-expression of Akt and GFP-RUNX3 significantly reversed RUNX3-reduced proliferation of AGS cells (Figure 2h, left panel) . In contrast, expression of dominant-negative Akt significantly blocked RUNX3 knockdown-induced cell proliferation of GES-1 cells (Figure 2h, right panel) .
As RUNX3 exhibits transcriptional activity in other systems, we hypothesized that Akt expression may be repressed by RUNX3 through transcriptional inhibition. By analyzing Akt1 promoter region, from nucleotides -4293 to þ 1888, two consensus binding sequences of RUNX3 'TGTGGT' were identified between nucleotides þ 417 and þ 422 (RBS1) and nucleotides þ 1089 and þ 1094 (RBS2) within Akt1 promoter region (Figure 3a) . Direct binding of RUNX3 to RBS1 and RBS2 sites of Akt1 promoter in Flag-RUNX3-overexpressing AGS cells was confirmed by chromatin immunoprecipitation (ChIP) assay using anti-Flag antibody (Figure 3b , left panel). ChIP assay on GES-1 cells by using RUNX3 antibody also demonstrated that the endogenous RUNX3 bound to both RBSs in Akt1 promoter (Figure 3b, right panel) . Furthermore, luciferase reporter assay showed the Akt1 promoter activity was repressed by RUNX3 in a dosedependent manner in AGS cells (Figure 3c) . Mutation of the RUNX3-binding sequence from 'TGTGGT' to 'TATAAT' for either RBS1 or RBS2 site partially abolished the repressive effect of RUNX3 on Akt1 promoter activity. However, double mutation of RBS1 and RBS2 completely reversed RUNX3-inhibited Akt1 promoter activity in RUNX3-overexpressing AGS cells (Figure 3d ). On the other hand, mutations of RBS1 and RBS2 or both sites in Akt1 promoter region significantly elevated Akt1 promoter activity in normal gastric epithelial cells, GES-1 (Figure 3e ). Knockdown of endogenous RUNX3 in GES-1 cells increased wild-type Akt1 promoter activity, although the mutations of RBS1 and/or RBS2 in Akt1 promoter had no additional effects on it (Figure 3e ). These results indicated that Figure 1 Overexpression of RUNX3 causes cell cycle arrest and inhibits cell proliferation. (a) Endogenous RUNX3 protein expression in clinical gastric tissues, normal gastric epithelial cell line, GES-1 and gastric cancer cell lines was assessed by western blot using specific antibody against RUNX3. (b) Colony-forming assay showed the number and size of colonies were reduced in Flag-RUNX3-overexpressing AGS cell cultures. Parental (mock) and pCMV control vector-transfected (pCMV) AGS cells were used as controls. The transfection efficiency of Flag-RUNX3 was confirmed by western blot using Flag antibody. The colony number was counted and shown in histogram. **Po0.01, compared with pCMV control group. (c) Cell proliferation assay was performed by counting the cell number at 0, 12, 24, 36 and 48 h after GFP or GFP-RUNX3 transfection in AGS cells. The expression of exogenous GFP and GFP-RUNX3 was examined by western blot using antibody against GFP (insert). (d) Overexpression of RUNX3 caused the cell cycle arrest at G1-phase. Cell cycle distribution of AGS cells was analyzed by flow cytometry at 24 h after GFP or GFP-RUNX3 transfection. **Po0.01, compared with GFP control group. (e) GFP-or GFP-RUNX3-transfected cells were synchronized by nocodazole (100 ng/ml) treatment for 14 h and then subjected to cell cycle distribution analysis.
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RUNX3 functions as a transcriptional repressor to Akt1 expression. To investigate whether the runt domain of RUNX3 is responsible for Akt1 transcription, we truncated different parts of RUNX3 protein to examine the importance of each domain of RUNX3 for Akt1 transcription inhibition. As shown in Figure 3f , both full-length and N-terminus (1-204 a.a.) of RUNX3 were sufficient for repression of Akt1 promoter activity, while the C-terminus (205-429 a.a.) of RUNX3 did not exhibit the repressive activity on it. Together, these results showed that RUNX3 directly binds to Akt1 promoter and represses its transcription.
RUNX3 attenuates the Akt1/b-catenin/cyclin D1 signaling pathway Cyclin D1 is a downstream effecter of Akt1/b-catenin signaling pathway, and preferentially binds and activates CDK4 and CDK6 at G1 phase to initiate the cell cycle progression (Osaki et al., 2004; Clevers, 2006; Malumbres and Barbacid, 2009) . Accordingly, we test whether expression of cyclin D1 and associated signaling molecules were affected by RUNX3. AGS and SNU-1 cells were transiently transfected with GFP-RUNX3 or GFP plasmid. The GFP-positive cells were sorted (Supplementary Figure S1 ) and subjected into western blot analysis. Overexpression of RUNX3 remarkably decreased Akt, b-catenin and cyclin D1 protein levels ( Figure 4a ). Consistent with the result of phospho-MAPK array (Figure 2b ), phosphorylation of GSK-3b at Ser-9 was also reduced in RUNX3-overexpressing cells ( Figure 4a ). Similar results were also observed in HeLa cells (Supplementary Figure S2) , suggesting this inhibitory effect of RUNX3 was not restricted to gastric cancer cells. On the other hand, knockdown of endogenous RUNX3 by shRNA induced Akt, b-catenin and cyclin D1 protein expression and GSK-3b phosphorylation at Ser-9 in GES-1 cells ( Figure 4a ). We next examine the expression of Akt, b-catenin and cyclin D1 in clinical specimens. Western blot demonstrated low level of RUNX3 and high levels of Akt, b-catenin and cyclin D1 in gastric cancer tissues, and the opposite expression pattern was identified in normal gastric tissues ( Figure 4b ). In addition, the quantitative realtime PCR (Q-PCR) analysis was used to evaluate the mRNA expression in seven N-T-paired gastric cancer specimens ( Figure 4c ). In 7/7 (100%) specimens, the RUNX3 mRNA levels were reduced in tumor parts compared with their adjacent normal tissues (P ¼ 0.018). Concurrently, the elevation of Akt (6/7, 85.7%; P ¼ 0.028) and cyclin D1 (7/7, 100%; P ¼ 0.018) mRNA was observed, while the levels of b-catenin mRNA were not altered (P ¼ 0.237). Consistent with mRNA expression pattern in clinical specimens, Q-PCR analysis showed that ectopic expression of GFP-RUNX3-repressed mRNA expression of Akt and cyclin D1 but not b-catenin in AGS cells (Figure 4d ). Knockdown of endogenous RUNX3 in GES-1 cells resulted in the upregulation of Akt and cyclin D1 mRNA expression without changing b-catenin mRNA levels ( Figure 4e ). Collectively, these results suggested that RUNX3 attenuated Akt1/b-catenin/cyclin D1 signaling pathway at least in part through repressing Akt1 but not b-catenin transcription.
RUNX3 reduces b-catenin nuclear localization, transactivation and protein stability To investigate the effect of RUNX3 on b-catenin, Flag-RUNX3 was overexpressed in AGS cells, and the expression level and localization of endogenous b-catenin were determined by immunofluorescence. In the cells without Flag-RUNX3 expression, the nuclear localization of endogenous b-catenin could be scarcely observed. High expression of exogenous Flag-RUNX3, which was distributed in both cytoplasm and nucleus, dramatically attenuated b-catenin expression, and lower expression of Flag-RUNX3, which was mainly localized in the nucleus, partially decreased the staining signal and nuclear localization of b-catenin (Figure 5a ). Quantitative analysis showed that only about 10% of RUNX3-positive cells harbored weak b-catenin expression, while b-catenin was strongly detected in 480% of RUNX3-negative cells and found to localize in the nucleus in about 40% of them ( Figure 5b ). This result indicated that RUNX3 repressed the expression and nuclear localization of b-catenin. As nuclear b-catenin correlated to its transactivational potential (Shtutman et al., 1999; MacDonald et al., 2009) , we next examined the impact of RUNX3 on b-catenin-dependent transcription by TOP/ FOP luciferase reporter assay. TOP-Luc vector, which was used for detecting b-catenin-dependent transcriptional activation, or FOP-Luc, which contains the mutated b-catenin-binding site, was co-transfected with b-catenin and/or GFP-RUNX3 into AGS cells. As shown in Figure 5c , exogenous expression of b-catenin significantly increased the luciferase activity that was repressed by GFP-RUNX3. However, ectopic expression of myr-Akt, constitutive active Akt, completely blocked GFP-RUNX3-reduced luciferase activity, indicating that 
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F-C Lin et al GSK-3b remained un-phosphorylated and active to phosphorylate b-catenin (Cross et al., 1995) , we reasonably hypothesized that RUNX3-repressed b-catenin expression through enhancing protein degradation of b-catenin. Therefore, we examined the protein stability of endogenous b-catenin by degradation assay. AGS cells were transfected with GFP-RUNX3 or GFP and then treated with cycloheximide (CHX), a translation inhibitor. The cell lysates were then collected at different time points for western blot analysis. Although GFP-RUNX3 was degraded with time, we found that overexpression of GFP-RUNX3 accelerated degradation of b-catenin when compared with GFP control (Figure 5d , top and middle panels, and Figure 5e ). Similarly, treatment of Akt inhibitor IV also facilitated b-catenin degradation in the presence of CHX, (Figure 5d , lower panel, and Figure 5e ). These results confirmed that RUNX3-reduced b-catenin nuclear localization, transactivation and protein stability, which may through inhibition of Akt signaling. 
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Restoration of cyclin D1 reverses RUNX3-mediated cell growth inhibition and cell cycle arrest Next, we aimed to verify the vital role of cyclin D1 in RUNX3-induced proliferation inhibition and cell cycle arrest. We co-overexpressed cyclin D1 and RUNX3 in AGS cells and examined the recovering effect of cyclin D1 on RUNX3-mediated cellular outcome. As shown in Figure 6a , ectopic expression of GFP-RUNX3 inhibited endogenous cyclin D1 expression and cell proliferation. However, co-transfection of GFP-cyclin D1 reversed RUNX3-induced proliferation inhibition from B30 to B80% compared with the GFP-transfected control cells at 48 h. In colony-forming assay, RUNX3-induced growth inhibition was also recovered by co-transfecting GFP-cyclin D1 (Figures 6b and c) . Furthermore, flow cytometry showed co-transfection of cyclin D1 in RUNX3-overexpressing AGS cells abolished the RUNX3-induced G1-phase arrest and increased G2/ M-phase distribution compared with GFP-RUNX3-overexpressing AGS cells. In our data, the S-phase populations showed no statistical difference between individual groups (Figure 6d ). These results indicated that suppression of cyclin D1 had an important role in RUNX3-induced proliferation inhibition and cell cycle 
arrest. Together, loss of RUNX3 activated the Akt1/bcatenin/cyclin D1 signaling pathway that promoted tumorigenesis process in gastric cancer.
Discussion
In this study, we demonstrated that RUNX3 transcriptionally represses Akt1 expression and the subsequent GSK-3b/b-catenin/cyclin D1 cascade. Enforced expression of RUNX3 in gastric cancer cells resulted in cell cycle arrest at G1 phase leading to proliferation inhibition. Knockdown of endogenous RUNX3 in normal gastric epithelial cells increased the expression and phosphorylation of Akt and promoter cell proliferation. RUNX3 downregulation of Akt1-promoted GSK-3b activation and b-catenin degradation leading to the inhibition of b-catenin-mediated cyclin D1 expression. Thus, we concluded that Akt1 overexpression in gastric cancer might associate with loss of RUNX3 and suggested a novel mechanism that RUNX3 participated in cell proliferation inhibition as a role of tumor suppressor ( Figure 7) . Overactivation of Akt in cancer cells is often regarded as the results of chromosome deletion, genetic mutation and gene amplification of the molecules that can regulate the activity of Akt, like PTEN deletion (Oki et al., 2005) and PIK3CA (PI3K) gene mutation . However, the genetic alternation of Akt itself is relatively low incidence in gastric cancer (Soung et al., 2006) . Recently, b-catenin/Tcd/Lef, STAT3 and CREB has been identified to regulate Akt1 promoter activity (Dihlmann et al., 2005; Park et al., 2005; Misra and Pizzo, 2007) . In addition, the binding sites of AP1, Sp1 and NF-kB on Akt1 promoter have also been predicted by software screening (Park et al., 2005) . Here, we are the first to show that RUNX3 can be a transcriptional repressor to Akt1. We have also identified the two RBSs on Akt1 promoter. In addition to the tumor-suppressor role of RUNX3 in TGF-b signaling pathway, we suggest a novel mechanism that RUNX3 can inhibit the transcription of Akt1; it also explains that loss of RUNX3 in major part of gastric cancer may contribute to the overexpression of Akt1.
RUNX3 can be a transcription activator or repressor through recruiting other transcriptional modulators to the promoter. It has been reported that RUNX3 interacts with mSin3 and Groucho/TLE, which associate with HDACs, and SUV39H1, a histone methyltransferase, to inhibit or silence the gene transcription (Durst and Hiebert, 2004) . The two binding sites for RUNX3 that we identified on Akt1 promoter are adjacent to the STAT3-binding motifs and b-catenin/ TCF-binding elements. It rises up the possibility that the binding of RUNX3 in this region also blocks other transcriptional activators binding to the promoter and represses the transcription. In addition, the RUNX family has been reported to interact with STATs and attenuate the transcription activity of each other by retaining the protein complex in the cytoplasm (Ogawa et al., 2008) . However, immunofluorescence and ChIP assay demonstrated that RUNX3 exactly localized in nuclei and bound to the promoter region of Akt1. Thus, further study is necessary to examine the cooperation of STAT3 and RUNX3 in Akt regulation.
Akt is one of the targets of b-catenin/TCF complex. RUNX3 has been reported that can interact with bcatenin/TCF complex to attenuate its transcriptional potential to the targeted genes in colorectal cancer . On the other hand, prostaglandin E2-induced activation of PI3K-PDK1-Akt signaling, which results in the phosphorylation and inactivation of GSK3b, leads to the stabilization and nuclear translocalization of b-catenin and promotes colon cancer cell growth (Castellone et al., 2005) . In our study, we demonstrated that the rapid degradation of b-catenin as a consequence of RUNX3-mediated Akt downregulation. We could not exclude the possibility that RUNX3 interacts with b-catenin/TCF complex before binding to Akt promoter, leading to the inhibition of Akt transcription. Although, this mechanism will not sustain because the b-catenin protein is absent in the end, suggesting the direct binding RUNX3 to Akt1 promoter would be the major event to inhibit Akt expression. Furthermore, the results from Ito et al. (2008) have shown that loss of RUNX3 in intestinal epithelial cells does not change the protein level of b-catenin, but in gastric cancer, we found that the b-catenin protein expression in RUNX3-deficient cancer tissues was higher than in normal tissues. It indicates the mechanisms about RUNX3 regulating b-catenin in Wnt pathway are different between colorectal and gastric cancers.
In previous studies, RUNX3 in gastric cancer has been considered to participate in TGF-b signaling pathway to inhibit cell growth and induce cell apoptosis. (Li et al., 2002; Wei et al., 2005; Hsu et al., 2009) . In agreement with others (Wei et al., 2005) , we found that cyclin D1 is a key molecule in RUNX3-induced cell cycle arrest at G1 phase and the restoration of cyclin D1 in RUNX3-overexpressed AGS cells can reverse most of the inhibition effect by RUNX3. This finding indicates that cyclin D1 is the critical target of RUNX3 in controlling the cell proliferation. We further demonstrated that RUNX3 can repress Akt1/GSK-3b/b-catenin/cyclin D1 pathway and suggested a new role of RUNX3 in proliferation inhibition besides TGF-b signaling pathway. In addition, the Akt overexpression and activation in gastric cancer has been considered that may repress the TGF-b signaling by inhibiting the activities of SMAD3 and FoxO3a to promote the cell survival (Brunet et al., 1999; Remy et al., 2004) ; it implies that RUNX3 represses Akt1 transcription not only to block the b-cateninmediated signaling but also to facilitate the TGF-b signaling possibly.
Cyclin D1 is commonly overexpressed in gastric cancer and mediates the growth factor-dependent G1-phase progression. We found that the inhibition of cyclin D1 in RUNX3-overexpressed AGS cells was through b-catenin-mediated transcriptional repression. Although we demonstrated that overexpression of RUNX3 attenuated the stability of b-catenin through the repression of Akt1/GSK-3b, however, it must be noticed that the genetic change of the b-catenin also occurs in gastric cancer. Several clinical studies indicated that the site-mutation leads b-catenin to accumulate and fail to degradation in gastric cancers, but the proportion of the mutated b-catenin is still in debate (Clements et al., 2002; Ebert et al., 2002) . Further studies will be necessary to investigate the association between RUNX3 and the genetic alternation of b-catenin in the tumorigenesis of gastric cancer.
From the result of degradation assay, we found that RUNX3 also degraded rapidly after CHX treatment. It seems that the subcellular environment of AGS cells is disadvantageous for maintaining RUNX3 protein stability. It has been reported that the acetylation of runt domain of RUNX3, which is mediated by p300 under the TGF-b stimulation, prevents it from ubiquitinationmediated degradation (Jin et al., 2004) . Rapid degradation of RUNX3 may be due to the character of AGS cells that fail to respond to TGF-b, and loss of TGF-b signaling and break down the cooperation between p300 and RUNX3 that we enforced expressed in. Moreover, Kim et al. (2009) have reported that RUNX3 can interact with Jab1/CSN5 in gastric cancer, and the Jab1/ CSN5 can mediate the nuclear export of RUNX3 and lead it to process the proteasome-dependent degradation in cytoplasm. In our previous study, we have found that RUNX3 expression could be found in 80% of the intestinal-type gastric cancer but was absent in the most of the diffuse-type (Hsu et al., 2009) . The genetic alternation between two types of gastric cancer may cause the different cellular situation for RUNX3 expression.
In conclusion, loss of RUNX3 in gastric cancer may contribute to Akt1 overexpression and promote the activation of Akt1-mediated downstream signaling. We consider that is important to elucidate the tumorigenesis process in gastric cancer associating with RUNX3 losing its function.
Materials and methods

Cell lines and cell culture
The human gastric cancer cell lines (AGS, NCI-N87, SNU-1, KATO III and NUGC-4) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained according to ATCC recommendations. The SV40-immortalized human normal gastric epithelial cell line, GES-1, was a gift from Dr Xiang Hong Zhang (Xing et al., 2011) and maintained in Dulbecco's modified Eagle's medium supplemented with 100 U/ml penicillin, 100 U/ml streptomycin and 10% fetal bovine serum. It has a phenotype much similar to normal stomach mucosal cells and does not grow into colonies in soft agar or tumor masses in nude mice. In addition, RUNX3 is highly expressed in GES-1 cells (Ke et al., 1994; Guo et al., 2005) .
Clinical specimens
Ninety gastric adenocarcinoma samples and corresponding noncancerous tissues were obtained with informed consent and the study was conducted under a protocol approved by the Institutional Review Board of Kaohsiung Veterans General Hospital of Taiwan. For Q-PCR analysis, seven gastric adenocarcinoma samples and corresponding noncancerous tissues were obtained from the tissue bank in National Cheng Kung University Hospital under a protocol approved by the Institutional Review Board of National Cheng Kung University Hospital of Taiwan.
Generation of recombinant plasmids
Flag-RUNX3, Flag-cyclin D1 and Flag-b-catenin plasmids were generated by insertion of human RUNX3 complementary DNA (cDNA) (nucleotides 1 to 1248; GenBank accession no. NM_004350), cyclin D1 cDNA (nucleotides 1 to 888; GenBank accession no. NM_053056) and b-catenin cDNA (nucleotides 1 to 2346; GenBank accession no. NM_001904) into the vectors pCMV2-Flag-CPO at the RsrII site, respectively. Fragments of RUNX3 cDNA encoding truncated RUNX3 protein and RUNX3 cDNA were also subcloned into the vector pEGFP to yield plasmids.
Gene transfection and colony-forming assay AGS cells were plated into six-well plates at a density of 1000 cells per well and transfected with indicated plasmid DNA using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) as per the manufacturer's instructions. After cells cultured for 14 days, individual colonies (450 cells per colony) were fixed and stained using a solution of crystal violet in methanol. The colonies were counted using a UMAX MagicScan (Techville, Inc., Dallas, TX, USA).
Flow cytometry analysis
Cells were prepared and stained with propidium iodide 24 h after transfection with indicated plasmid DNA. For cell-cycle analysis, 10 000 stained cells were sorted using a fluorescence-activated cell sorter (BD Biosciences, La Jolla, CA, USA) and data were analyzed using the Modfit software (BD Biosciences).
Human phospho-kinase array
The total proteins from whole cells were purified 24 h after transfection with pEGFP-RUNX3. The cell lysates were applied and incubated with the human phospho-MAPK Array Kit (R & D Systems, Minneapolis, MN, USA) as per the manufacturer's instructions. The data were quantified by using NIH image software analysis (Universal Imaging Corp., Downingtown, PA, USA).
Western blot analysis
Cells or tissues were lysed in RIPA buffer or Giordano buffer, respectively. Western blot analysis was performed using anti-Akt (9272; Cell Signaling, Beverly, MA, USA), antiphosphorylated Akt (Ser-473) (9271; Cell Signaling), antiphosphorylated Akt (Thr-308) (4056; Cell Signaling), anti-GSK-3b (9315; Cell Signaling), anti-phosphorylated GSK-3b (Ser-9) (9336; Cell Signaling), anti-b-catenin (sc-7963; Santa Cruz), anti-cyclin D1 (sc-718; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-GFP (sc-9996; Santa Cruz), antiFlag M2 (F1804; Sigma, St Louis, MO, USA), anti-b-actin (A5441; Sigma) and anti-RUNX3 (obtained as previously described (Hsu et al., 2009) Reverse: 5 0 -CTCCTAAATTATAGCGCCCCTG-3 0 . For evaluating b-catenin transactivation, TOPflash and FOPflash luciferase reporter plasmids were gifts of Dr Randall Moon (Addgene plasmid #12456 and 12457, respectively). All the experimental groups were co-transfected with renilla luciferase plasmids as an internal control. The firefly luciferase activity of TOPflash and FOPflash was normalized with the readings of renilla luciferase activity, and the ratio of TOPflash/ FOPflash (TOF/FOP-luc) was calculated. To examine whether RUNX3-reduced transcriptional activity of b-catenin is mediated by Akt, in some groups, constitutively activated Akt, myr-Akt, was co-transfected with b-catenin in GFP-RUNX3-or GFPtransfected cells. AGS cells were co-transfected with indicated reporter and expressing plasmids. At 24 h after transfection, cells were harvested and luciferase activity was measured by Luminoskan Ascent microplate luminometer (Thermo Labsystems Inc., Franklin, MA, USA).
RUNX3 shRNA lentivirus preparation
The pGIPZ-RUNX3-shRNA was purchased from Invitrogen (clone no. 364943). The pGIPZ-RUNX3-shRNA and pGIPZ lentiviral vector-only lentivirus particles were prepared by cotransfection with packaging plasmid PAX2 and enveloping plasmid MD2G into HEK293T cells. A complete medium change was performed at 6 h after transfection and the medium containing viral particles was collected at day 2 and day 3 and transferred to a fresh 50 ml tube and centrifuged at 1000 r.p.m. for 5 min. Supernatant was filtered through 0.45 mm filter (Pall Corporation, Ann Arbor, MI, USA). The lentiviral stock was frozen in a 5 ml aliquot and stored at À80 1C until use.
ChIP assay AGS and GES-1 cells were transfected with Flag-RUNX3 and infected with lentivirus carrying RUNX3 shRNA respectively. ChIP assay was performed using the ChIP assay kit (Upstate Biotechnology, Lake Placid, NY, USA) with the anti-Flag antibody (F1804; Sigma), anti-RUNX3 (ab11905; Abcam, Cambridge, MA, USA) or normal mouse/rabbit immunoglobulin G (Millipore, Billerica, MA, USA). The primers used to amplify the DNA fragment were designed as follow: Immunohistochemistry Tissues were fixed with 10% formalin, embedded in paraffin, and sectioned (4 mm). Anti-RUNX3 (R3-6E9; MBL, Woburn, MA, USA) and anti-Akt (4685; Cell Signaling) antibodies were applied on rehydrated retrieved sections. A positive reaction was indicated by a reddish-brown precipitate in the nucleus for RUNX3 expression, and in the nucleus or cytoplasm for Akt expression. Expression levels were visualized and classified based on the percentage of positive cells and the intensity of staining. Specifically, the percentage of positive cells was divided into five grades (percentage cores): %10% (0), 11-25% (1), 26-50% (2), 51-75% (3) and 475% (4). Intensity of staining was divided into four grades (intensity scores): no staining (0), light brown (1), brown (2) and dark brown (3). The staining positivity was determined by the formula: overall scores ¼ percentage score Â intensity score. Overall score of %2 was defined as negative, score of 42 but %4 as weakly positive (1 þ ), score of 44 but %8 as moderately positive (2 þ ) and score of 48 as strongly positive (3 þ ).
Immunofluorescence studies Flag-RUNX3-transfected AGS cells were grown on coverslips. After fixation and permeation, samples were incubated with anti-RUNX3 or anti-b-catenin antibody and then with rhodamine-or fluorescein isothiocyanate-conjugated secondary antibody (Santa Cruz) respectively. Immunofluorescence microscopy was used for analysis.
Degradation assay
At 24 h after GFP or GFP-RUNX3 transfection, the AGS cells were treated with 100 mg/ml CHX (C0378; Sigma). In some experiments, GFP-transfected AGS cells were pretreated with 3 mg/ml Akt inhibitor IV (124011; Merck, Whitehouse Station, NJ, USA) for 10 min. After pre-treatment, CHX was applied into the medium. The total cell lysates were collected immediately and at 2, 4, 8 and 12 h after CHX treatment. The protein levels were analyzed by western blot and quantified by relative expression of actin.
Statistical analysis
Statistical evaluation was performed with SPSS software (version 11.05, SPSS Inc., Chicago, IL, USA). For in vitro studies, each experiment was done independently at least twice with similar results. Continuous data were presented as mean±s.e.m. and compared between two groups by Student's unpaired t-test. The correlation between RUNX3 and AKT expressions in paraffin-embedded tissues was determined by Kendall tau-c correlation coefficient. Po0.05 was considered statistically significant (*Po0.05, **Po0.01 and ***Po0.001). The mRNA expression of RUNX3, Akt, cyclin D1 and b-catenin between normal and tumor parts of clinical specimens was analyzed using Wilcoxon Signed-Rank Test.
